Tilia Fiduciary Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$928K Buy
1,009
+80
+9% +$81.1K 0.51% 55
2025
Q4
$998K Sell
929
-72
-7% -$68.8K 0.55% 54
2025
Q3
$764K Sell
1,001
-5
-0.5% -$3.72K 0.44% 60
2025
Q2
$784K Hold
1,006
0.48% 60
2025
Q1
$831K Hold
1,006
0.55% 57
2024
Q4
$777K Sell
1,006
-46
-4% -$38.1K 0.53% 56
2024
Q3
$932K Buy
1,052
+15
+1% +$13.5K 0.65% 50
2024
Q2
$939K Sell
1,037
-15
-1% -$12K 0.73% 49
2024
Q1
$818K Sell
1,052
-4
-0.4% -$2.85K 0.66% 52
2023
Q4
$615K Sell
1,056
-179
-14% -$104K 0.57% 61
2023
Q3
$663K Sell
1,235
-19
-2% -$9.79K 0.69% 53
2023
Q2
$588K Buy
1,254
+12
+1% +$5.03K 0.53% 58
2023
Q1
$427K Sell
1,242
-18
-1% -$6.07K 0.41% 68
2022
Q4
$461K Sell
1,260
-213
-14% -$75.5K 0.44% 69
2022
Q3
$483K Sell
1,473
-2,054
-58% -$651K 0.49% 64
2022
Q2
$1.14M Buy
3,527
+12
+0.3% +$3.6K 1.09% 22
2022
Q1
$1.01M Buy
3,515
+82
+2% +$21.1K 0.85% 41
2021
Q4
$948K Buy
+3,433
New +$870K 0.76% 44

Other funds holding LLY

Tilia Fiduciary Partners's LLY Position: Q1 2026 in Review

Tilia Fiduciary Partners increased its Eli Lilly (LLY) stake by 8.6% in Q1 2026, buying an estimated $81.1K and bringing the position to 1,009 shares worth $928K. The position accounts for 0.51% of the portfolio, ranked #55.

Tilia Fiduciary Partners first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.14M in Q2 2022. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Tilia Fiduciary Partners held 1,009 shares of Eli Lilly worth $928K as of Q1 2026.
  • Tilia Fiduciary Partners bought 80 Eli Lilly shares in Q1 2026, an estimated $81.1K.
  • Eli Lilly made up 0.51% of Tilia Fiduciary Partners's portfolio in Q1 2026, its #55 holding.
  • Tilia Fiduciary Partners first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Tilia Fiduciary Partners's Eli Lilly position peaked at $1.14M in Q2 2022.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Tilia Fiduciary Partners's 13F filing for Q1 2026, filed 9 Apr 2026.